{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:37:49Z","timestamp":1790271469624,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.oret.2020.03.017","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T19:41:35Z","timestamp":1585770095000},"page":"871-880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"4","author":[{"given":"Kelvin Yi Chong","family":"Teo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6717-4975","authenticated-orcid":false,"given":"Nakul","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3734","authenticated-orcid":false,"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2020.03.017_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2020.03.017_bib2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2020.03.017_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2020.03.017_bib4","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2020.03.017_bib5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib8","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OPTH.S185052","article-title":"The burden of neovascular age-related macular degeneration: a patient\u2019s perspective","volume":"12","author":"Spooner","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib10","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND Study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","article-title":"Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol","volume":"125","author":"Adrean","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/IAE.0000000000001496","article-title":"Two year outcomes of \u201ctreat and extend\u201d intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration","volume":"38","author":"Barthelmes","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.03.017_bib14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib15","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","article-title":"Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration","volume":"123","author":"Essex","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","volume":"12","author":"Ehlken","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib17","first-page":"88","article-title":"[The influence of patient compliance with antiangiogenic therapy on its efficacy for neovascular age-related macular degeneration]","volume":"130","author":"Bobykin","year":"2014","journal-title":"Vestn Oftalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib18","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","article-title":"Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life","volume":"251","author":"Droege","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1755-3768.2012.02493.x","article-title":"Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study\u2014a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany","volume":"91","author":"Finger","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE Study","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.03.017_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00417-017-3890-8","article-title":"An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER Study","volume":"256","author":"Eldem","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":"Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib23","first-page":"1849","article-title":"Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS Study","volume":"7","author":"Rakic","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.oret.2019.10.019","article-title":"Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians","volume":"4","author":"Fenner","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2020.03.017_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101057","article-title":"A\u00a0prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"9","author":"Cheung","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.oret.2020.03.017_bib27","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib28","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ophtha.2013.09.050","article-title":"Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ophtha.2018.08.023","article-title":"Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration","volume":"126","author":"Nguyen","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high-quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project","volume":"34","author":"Gillies","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.03.017_bib31","author":"Bates"},{"key":"10.1016\/j.oret.2020.03.017_bib32","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","article-title":"Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA Study","volume":"100","author":"Holz","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib33","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1167\/iovs.13-11993","article-title":"Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes","volume":"54","author":"Gillies","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2020.03.017_bib34","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2019.02.005","article-title":"Randomized trial of treat and extend ranibizumab with and without navigated laser versus monthly dosing for diabetic macular edema: TREX-DME 2-year outcomes","volume":"202","author":"Payne","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib36","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib37","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2014a phase IV randomised clinical trial with ranibizumab: the FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4274\/tjo.28003","article-title":"Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration","volume":"47","author":"Polat","year":"2017","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4274\/tjo.28003","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"47","author":"Polat","year":"2017","journal-title":"Turkish J Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/09286586.2012.751429","article-title":"Lack of awareness of common eye conditions in the community","volume":"20","author":"Huang","year":"2013","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.oret.2020.03.017_bib42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/eye.2015.159","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2020.03.017_bib43","first-page":"5","article-title":"Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision","volume":"39","author":"Shona","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.017_bib44","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.017_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12955-016-0536-1","article-title":"Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN Study","volume":"14","author":"Bertelmann","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.oret.2020.03.017_bib46","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/OPX.0000000000000283","article-title":"Trends in age-related macular degeneration management in Singapore","volume":"91","author":"Ng","year":"2014","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.oret.2020.03.017_bib47","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID Study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020301196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020301196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:28:40Z","timestamp":1762853320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653020301196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2468653020301196"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2020.03.017","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2020.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}